NEW YORK (GenomeWeb News) – German protein reagents and sample prep technology firm Caprotec Bioanalytics said yesterday that it has closed on a €4 million ($5 million) Series B financing round.
Proceeds will be used to further develop its Capture Compound Mass Spectrometry technology for analyzing complex protein mixtures, the firm said in a statement. Specifically, Caprotec will continue development of its caproKits for the identification of functionally selected protein classes, as well as its ImproMed application for profiling drug interactions.
Participants in the financing included existing investors Creathor Venture, IBB Beteiligungsgesellshaft, ERP Startfonds, and private investors, the Berlin-based company said.
Caprotec's technology, called CCMS, is based on tri-functional molecules called capture compounds, and can be used to define and confirm drug targets and to discover off-target proteins that cause side effects.